Literature DB >> 28507203

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Jessica M Moskovitz1, Jennifer Moy1, Tanguy Y Seiwert2,3, Robert L Ferris4,5,6.   

Abstract

Advances in the field of cancer immunotherapy have occurred rapidly over the past decade. Exciting results from clinical trials have led to new treatment options and improved survival for patients with a myriad of solid tumor pathologies. However, questions remain unanswered regarding duration and timing of therapy, combination regimens, appropriate biomarkers of disease, and optimal monitoring of therapeutic response. This article reviews emerging immunotherapeutic agents and significant clinical trials that have led to advancements in the field of immuno-oncology for patients with head and neck squamous cell carcinoma. IMPLICATIONS FOR PRACTICE: This review article summarizes recently developed agents that harness the immune system to fight head and neck squamous cell carcinoma. A brief review of the immune system and its role in cancer development is included. Recently completed and emerging therapeutic trials centering on the immune system and head and neck cancer are reviewed. © AlphaMed Press 2017.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; Immunotherapy; Lymphocyte; Neoplasm of head and neck

Mesh：

Substances：

Year:  2017        PMID： 28507203      PMCID： PMC5469583          DOI： 10.1634/theoncologist.2016-0318

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  80 in total

1.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.

Authors:  Timothy A Chan; Jedd D Wolchok; Alexandra Snyder
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.

Authors:  Paramita Baruah; Michael Lee; Tunde Odutoye; Peter Williamson; Nicholas Hyde; Juan Carlos Kaski; Ingrid E Dumitriu
Journal:  Immunobiology       Date:  2011-11-22       Impact factor: 3.144

Review 4.  Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

Authors:  Jacques Bernier; Jay S Cooper
Journal:  Oncologist       Date:  2005-03

5.  Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines.

Authors:  M R Posner; L A Cavacini; M P Upton; K C Tillman; E R Gornstein; C M Norris
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 6.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.

Authors:  Sumita Trivedi; Raghvendra M Srivastava; Fernando Concha-Benavente; Soldano Ferrone; Tatiana M Garcia-Bates; Jing Li; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2016-05-23       Impact factor: 12.531

Review 9.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

10.  Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Authors:  Stéphane Champiat; Charles Ferté; Sophie Lebel-Binay; Alexander Eggermont; Jean Charles Soria
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110
View more
  13 in total

1.  Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.

Authors:  Bangrong Cao; Qifeng Wang; Huan Zhang; Guiquan Zhu; Jinyi Lang
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

2.  A transcriptional metabolic gene-set based prognostic signature is associated with clinical and mutational features in head and neck squamous cell carcinoma.

Authors:  Lu Xing; Mingzhu Guo; Xiaoqi Zhang; Xiaoqian Zhang; Feng Liu
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-17       Impact factor: 4.553

3.  M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF.

Authors:  Enhui Fu; Tianyang Liu; Siyang Yu; Xiaohang Chen; Lianhao Song; Huihuang Lou; Fen Ma; Siwei Zhang; Sajjad Hussain; Junnan Guo; Ji Sun; Pingyang Yu; Xionghui Mao; Lanlan Wei
Journal:  Oncol Rep       Date:  2020-05-29       Impact factor: 3.906

4.  Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".

Authors:  Cornelius Maihoefer; Lars Schüttrumpf; Corinna Macht; Ulrike Pflugradt; Julia Hess; Ludmila Schneider; Christine Woischke; Axel Walch; Philipp Baumeister; Thomas Kirchner; Horst Zitzelsberger; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2018-07-03       Impact factor: 3.481

Review 5.  Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

Authors:  Fabio Pagni; Elena Guerini-Rocco; Anne Maria Schultheis; Giulia Grazia; Erika Rijavec; Michele Ghidini; Gianluca Lopez; Konstantinos Venetis; Giorgio Alberto Croci; Umberto Malapelle; Nicola Fusco
Journal:  Int J Mol Sci       Date:  2019-11-01       Impact factor: 5.923

Review 6.  Tumor immune microenvironment in head and neck cancers.

Authors:  Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

7.  PD-L1 expression in recurrent head and neck squamous cell carcinoma.

Authors:  Alice Delafoy; Arnaud Uguen; Gilles Lemasson; Virginie Conan-Charlet; Olivier Pradier; François Lucia; Ulrike Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-04-01       Impact factor: 2.503

8.  Association between APOBEC3H-Mediated Demethylation and Immune Landscape in Head and Neck Squamous Carcinoma.

Authors:  Qin Liu; Yue-Wen Luo; Ruo-Yan Cao; Xue Pan; Xi-Juan Chen; Si-Yuan Zhang; Wei-Lin Zhang; Jia-Ying Zhou; Bin Cheng; Xian-Yue Ren
Journal:  Biomed Res Int       Date:  2020-07-24       Impact factor: 3.411

9.  Patient-reported outcomes in head and neck cancer: prospective multi-institutional patient-reported toxicity.

Authors:  M Sean Peach; Daniel M Trifiletti; Carolyn Vachani; Karen Arnold-Korzeniowski; Christina Bach; Margaret Hampshire; James M Metz; Christine E Hill-Kayser
Journal:  Patient Relat Outcome Meas       Date:  2018-07-27

10.  Expression scoring of a small-nucleolar-RNA signature identified by machine learning serves as a prognostic predictor for head and neck cancer.

Authors:  Lu Xing; Xiaoqi Zhang; Xiaoqian Zhang; Dongdong Tong
Journal:  J Cell Physiol       Date:  2020-01-14       Impact factor: 6.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.